Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 17,750 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the sale, the director directly owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $35.03 on Thursday. The firm has a 50 day moving average price of $30.00 and a two-hundred day moving average price of $27.11. The stock has a market cap of $25.20 billion, a P/E ratio of -58.38 and a beta of 1.10. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Institutional Trading of Roivant Sciences

A number of large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its stake in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the period. American Century Companies Inc. grew its stake in Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. increased its holdings in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp increased its holdings in Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ROIV has been the topic of a number of analyst reports. Guggenheim upped their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Sanford C. Bernstein began coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.